Psilocybin affects men and women differently, with sex-linked differences in psychedelic intensity, side effects, and therapeutic response

Psilocybin appears to affect men and women differently, with emerging evidence pointing to sex-linked variation in acute psychedelic intensity, adverse effects, and clinical outcomes. Biological factors such as hormones, body composition, metabolism, and serotonin system differences may shape how the drug is experienced and how benefits unfold over time. Women may report stronger subjective effects or different side-effect patterns at similar doses, while men and women can also differ in psychiatric baseline, treatment response, and vulnerability to specific risks. These differences matter because psychedelic research has often underexamined sex as a variable, limiting dose optimization and safety planning. Sex-specific analysis could improve trial design, help clinicians tailor preparation and follow-up, and make psilocybin therapy more precise. Better inclusion and reporting standards may also clarify whether current treatment models overlook important biological and psychosocial differences.